{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:22:10Z","timestamp":1787829730420,"version":"build-2784847793"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,29]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Lipid-lowering drugs are currently widely used by clinicians in clinical practice; numerous related studies have confirmed the pivotal role of the lipid pathway in regulating platelet function. Lipid-lowering drugs, represented by statins, have been found to have an improving effect on platelet-related diseases. However, there is a lack of large-scale population studies at present, and the causal explanation of traditional observational design studies is easily limited by confounding variables. The impact of lipid-lowering drugs on the risk of essential hemorrhagic thrombocythemia is not clearly understood. Our study sought to investigate the causal association between essential hemorrhagic thrombocythemia and lipid-lowering drugs through a drug-target Mendelian randomization (MR) analysis. We utilized the data from the Global Lipid Genetics Consortium to identify instrumental variables for 3 types of lipid-lowering drugs (3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, proprotein convertase subtilisin\/kexin type 9 [PCSK9] inhibitors, and NPC1-like intracellular cholesterol transporter 1 [NPC1L1] inhibitors). We obtained the genome-wide association study data for essential hemorrhagic thrombocythemia from the FinnGen study. We employed the MR method based on aggregated data and the inverse variance weighted method for the analysis. Sensitivity analyses were conducted using the conventional MR method. By analyzing data from 1171 patients with essential hemorrhagic thrombocythemia and about 1.3 million individuals with low-density lipoprotein (LDL) testing, PCSK9 inhibition was associated with a significantly increased risk of essential hemorrhagic thrombocythemia (odds ratio [OR], LDL ratio of 1.87 for every 1 standard deviation increased; 95% confidence interval [CI]\u2005=\u20051.2\u20132.91;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.02). NPC1L1 inhibition was associated with a reduced risk of essential hemorrhagic thrombocythemia (OR, LDL 0.19 for every 1 standard deviation reduction; 95% CI\u2005=\u20050.05\u20130.73;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.03). No association was found between 3-hydroxy-3-methylglutaryl-CoA reductase inhibition and essential hemorrhagic thrombocythemia (OR\u2005=\u20050.76, 95% CI\u2005=\u20050.34\u20131.69,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.51). The results of this MR study suggest that NPC1L1 inhibition is causally associated with a reduction in primary hemorrhagic thrombocythemia, whereas PCSK9 inhibition was positively correlated with the occurrence of the disease, which provided a new clue for the future treatment of essential hemorrhagic thrombocythemia.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049077","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:08:19Z","timestamp":1780074499000},"page":"e49077","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Lipid-lowering drugs and essential hemorrhagic thrombocythemia\u2019s risk: A drug-target Mendelian randomization study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1441-5643","authenticated-orcid":false,"given":"Peng","family":"Zhang","sequence":"first","affiliation":[{"name":"Changchun University of Traditional Chinese Medicine, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaiJiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MingHao","family":"Lin","sequence":"additional","affiliation":[{"name":"Changchun University of Traditional Chinese Medicine, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Dai","sequence":"additional","affiliation":[{"name":"Changchun University of Traditional Chinese Medicine, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhong","sequence":"additional","affiliation":[{"name":"Changchun University of Traditional Chinese Medicine, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RuoLin","family":"Wang","sequence":"additional","affiliation":[{"name":"Changchun University of Traditional Chinese Medicine, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Sheng","sequence":"additional","affiliation":[{"name":"Changchun University of Traditional Chinese Medicine, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"He","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Nan","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260827","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1182\/blood.2022017625","article-title":"Essential thrombocythemia: challenges in clinical practice and future prospects.","volume":"141","author":"Godfrey","year":"2023","journal-title":"Blood"},{"key":"R2-20260827","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"key":"R3-20260827","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","article-title":"Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.","volume":"63","author":"Verstovsek","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"R4-20260827","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/17474086.2019.1585239","article-title":"Developments in diagnosis and treatment of essential thrombocythemia.","volume":"12","author":"Mora","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"R5-20260827","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1172\/JCI107971","article-title":"Platelet hypersensitivity induced by cholesterol incorporation.","volume":"55","author":"Shattil","year":"1975","journal-title":"J Clin Invest"},{"key":"R6-20260827","doi-asserted-by":"crossref","first-page":"11739","DOI":"10.3390\/ijms241411739","article-title":"The effects of statins, ezetimibe, PCSK9-inhibitors, inclisiran, and icosapent ethyl on platelet function.","volume":"24","author":"Di Costanzo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R7-20260827","doi-asserted-by":"crossref","first-page":"e1003898","DOI":"10.1371\/journal.pmed.1003898","article-title":"The evolution of Mendelian randomization for investigating drug effects.","volume":"19","author":"Gill","year":"2022","journal-title":"PLoS Med"},{"key":"R8-20260827","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data.","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"key":"R9-20260827","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41586-021-04064-3","article-title":"The power of genetic diversity in genome-wide association studies of lipids.","volume":"600","author":"Graham","year":"2021","journal-title":"Nature"},{"key":"R10-20260827","doi-asserted-by":"crossref","first-page":"k601","DOI":"10.1136\/bmj.k601","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians.","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ"},{"key":"R11-20260827","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/ije\/dyr036","article-title":"Avoiding bias from weak instruments in Mendelian randomization studies.","volume":"40","author":"Burgess","year":"2011","journal-title":"Int J Epidemiol"},{"key":"R12-20260827","doi-asserted-by":"crossref","first-page":"e1004383","DOI":"10.1371\/journal.pgen.1004383","article-title":"Bayesian test for colocalisation between pairs of genetic association studies using summary statistics.","volume":"10","author":"Giambartolomei","year":"2014","journal-title":"PLoS Genet"},{"key":"R13-20260827","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamadermatol.2022.6051","article-title":"Association of lipid-lowering drugs with risk of psoriasis: a Mendelian randomization study.","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"key":"R14-20260827","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease.","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"key":"R15-20260827","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/CIRCULATIONAHA.115.018531","article-title":"Circulating proprotein convertase subtilisin\/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors.","volume":"133","author":"Leander","year":"2016","journal-title":"Circulation"},{"key":"R16-20260827","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2017.07.743","article-title":"Relationship of PCSK9 and urinary thromboxane excretion to cardiovascular events in patients with atrial fibrillation.","volume":"70","author":"Pastori","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R17-20260827","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2017.11.069","article-title":"PCSK9 as a positive modulator of platelet activation.","volume":"71","author":"Camera","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R18-20260827","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","article-title":"PCSK9 (proprotein convertase subtilisin\/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36.","volume":"143","author":"Qi","year":"2021","journal-title":"Circulation"},{"key":"R19-20260827","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.numecd.2019.09.012","article-title":"Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: a 12-month follow-up.","volume":"30","author":"Barale","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R20-20260827","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2174\/0929867323666160229114111","article-title":"Niemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases.","volume":"23","author":"Pirillo","year":"2016","journal-title":"Curr Med Chem"},{"key":"R21-20260827","doi-asserted-by":"crossref","first-page":"704501","DOI":"10.3389\/fcvm.2021.704501","article-title":"Effect of NPC1L1 and HMGCR genetic variants with premature triple-vessel coronary disease.","volume":"8","author":"Zhao","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R22-20260827","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/1440-1681.13599","article-title":"Effect of NPC1L1 polymorphism on warfarin stable dose in Chinese patients under heart valve replacement surgery.","volume":"49","author":"Ma","year":"2022","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R23-20260827","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJM198807073190105","article-title":"HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.","volume":"319","author":"Grundy","year":"1988","journal-title":"N Engl J Med"},{"key":"R24-20260827","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/cvr\/cvab032","article-title":"Emerging views of statin pleiotropy and cholesterol lowering.","volume":"118","author":"Yu","year":"2022","journal-title":"Cardiovasc Res"},{"key":"R25-20260827","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00001721-200408000-00004","article-title":"Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients.","volume":"15","author":"Malyszko","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R26-20260827","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/01.CIR.0000025419.95769.F0","article-title":"Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy.","volume":"106","author":"Cipollone","year":"2002","journal-title":"Circulation"},{"key":"R27-20260827","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0008-6363(03)00515-7","article-title":"Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.","volume":"59","author":"Mulhaupt","year":"2003","journal-title":"Cardiovasc Res"},{"key":"R28-20260827","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.amjcard.2004.04.037","article-title":"Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia.","volume":"94","author":"Hwang","year":"2004","journal-title":"Am J Cardiol"},{"key":"R29-20260827","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.mbc.0000161563.36270.a2","article-title":"CD40-ligand-dependent induction of COX-2 gene expression in endothelial cells by activated platelets: inhibitory effects of atorvastatin.","volume":"16","author":"Mosheimer","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R30-20260827","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2362.2005.01446.x","article-title":"Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients.","volume":"35","author":"Puccetti","year":"2005","journal-title":"Eur J Clin Invest"},{"key":"R31-20260827","doi-asserted-by":"crossref","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.1","article-title":"Mendelian randomization for studying the effects of perturbing drug targets.","volume":"6","author":"Gill","year":"2021","journal-title":"Wellcome Open Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:01:49Z","timestamp":1787828509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":31,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049077","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"2025-02-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}